Guide
Updated July 23, 2026
Fact-checked by Dr. J. Adam, MD on . See our fact-checking policy.
30+ of the most common questions patients ask before starting a GLP-1 program.
These are the questions patients ask most often before starting a GLP-1 program. Answers reflect current clinical guidance.
FDA-approved indications for weight-loss GLP-1s require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Off-label compounded prescribing for patients outside these criteria is at the discretion of the prescribing clinician.
Most patients notice appetite suppression within the first 1-2 weeks. Meaningful weight change typically appears by week 4-8. Trial mean weight loss at 72 weeks: Wegovy 2.4 mg ~14.9%, Zepbound 15 mg ~22.5%.
GLP-1 therapy is typically a long-term commitment. STEP-4 and SURMOUNT-4 trial data show significant weight regain after discontinuation. Patients and clinicians should plan for either continued therapy at a maintenance dose or a structured taper with intensive lifestyle support.
No formal contraindication, but many patients experience reduced alcohol tolerance and lose interest in alcohol on GLP-1s. If you do drink, hydrate aggressively and watch for amplified GI effects. See our dedicated GLP-1 and alcohol guide for more.
Semaglutide has been studied in long-term cardiovascular outcomes trials (SUSTAIN-6, SELECT) showing cardiovascular benefit. Tirzepatide cardiovascular outcomes trials (SURPASS-CVOT) are reading out through 2026. The general safety profile is well characterized for the durations studied.
Without continued therapy or intensive lifestyle support, yes; most patients regain a substantial portion. With continued therapy, weight is generally maintained at the new lower set point. See our stopping GLP-1 guide for more.
Trial means: Wegovy 2.4 mg ~14.9% (STEP-1), Zepbound 15 mg ~22.5% (SURMOUNT-1). Individual results vary widely.
Resistance training is strongly recommended to preserve lean mass. Cardio is helpful but not as protective for body composition.
Most medications are compatible. GLP-1s slow gastric emptying, which can affect timing of oral medications. Discuss your full medication list with your clinician.
With insurance approval, brand-name Wegovy or Zepbound at $25-$50 copay. Without insurance, NexLife at $119/month for compounded semaglutide is our editor's pick on price, transparency, and clinical oversight.
For physician-led GLP-1 care at $119–$139/mo flat-rate compounded sema, our 2026 editor's pick is NexLife. LegitScript-certified, . Visit NexLife →
Editorial note. This guide is for educational purposes only and does not constitute medical advice. Always consult a licensed clinician about your specific situation.